Participated · Equity · Dec 2025

Pan Cancer T is a Rotterdam-based biotech spin-out from Erasmus MC (founded in 2020) that engineers TCR-T cell therapies for hard-to-treat solid cancers. Its platform pairs broadly expressed tumour targets with proprietary technologies designed to enhance T-cell durability, aiming to improve efficacy against solid tumours. The lead program, PCT1:CO-STIM, is being prepared for a first-in-human trial in women with triple-negative breast cancer. Additional pipeline programs address malignancies of the skin, colorectum, stomach, oesophagus, ovary and uterus. To date the company has secured roughly €21 million in capital, comprising €2 million in grants, an Innovation Credit loan and multiple equity financings. The latest infusion strengthens its cash position to advance pre-clinical work through the clinic while expanding its broader solid-tumour pipeline. Existing investors continue to back the firm alongside non-dilutive government support, reflecting confidence in its differentiated approach.

Participated · Equity · Apr 2019

Ceradis is a Dutch biotech company that develops environmentally friendly plant nutrition and crop protection products. The team spent more than a decade developing a line of biologicals and now markets 13 product variations through distribution partners. Its offerings are entrapment solutions that slow the release of active ingredients so farmers can reduce chemical application rates rather than fully replace chemicals. Ceradis’ new biofungicide CeraMax is derived from a bacteria molecule, targets only fungi, has a long shelf life, and is expected to be tolerance-exempt under the U.S. EPA. With fresh funding, the company plans to develop and register crop-specific formulations of CeraMax in the U.S., initially targeting high-value applications like seed and post-harvest treatment before pursuing mass-market use. The company launched in 2007 out of Wageningen University, focuses on R&D and intellectual property, and distributes products through partners including Syngenta and Dole. Ceradis is a Wageningen University spin-off based in Wageningen, the Netherlands, that develops patented fungicides for a broad range of fruit and vegetable crops. Its products are applicable to crops including potato, tomato, grape, banana and pineapple. The company’s fungicides are designed to reduce chemical residues. Ceradis is led by Wim van der Krieken (CEO and Chief Scientist), Desiree Engelen (COO and Regulatory Affairs/IP) and Johan Grootscholten (Sales & Marketing manager NA & EMEA). The company raised funding to accelerate its growth and expansion efforts. The financing and product focus aim to support commercialization and market adoption in NA and EMEA.

Participated · Equity · Apr 2017

Sensara provides a senior lifestyle monitoring service built from movement sensors (no cameras), a self-learning algorithm that recognizes individual behavior patterns and detects deviations, and an application that sends notifications to caretakers or family members. The product is sold to senior care institutions and home care organizations to enable early detection of changes in lifestyle and prevent crisis situations. Founded in 2013 as a spin-off of Dutch research organization TNO, the company is led by CEO Reinout Engelberts. Sensara raised €3.8m in funding to support its operations. The company intends to use the funds to scale up sales, continue product development, broaden customer service and expand internationally. The round was led by KPN Ventures with participation from Van Herk Ventures and the company’s management.

Participated · Series B · Jul 2016

NightBalance develops and markets the Sleep Position Trainer (SPT), a chest-worn device that measures sleep position and gently nudges users to avoid supine positional obstructive sleep apnea. The SPT is CE-marked since 2012 and is currently sold in 11 European countries. NightBalance cites a wealth of clinical data demonstrating the device’s efficacy and improved patient compliance. The company plans to intensify commercial rollout across Europe and prepare entry into the U.S. market. Preparations include further U.S. clinical studies guided by Prof. Dr. David P. White and a planned U.S. FDA 510(k) filing. NightBalance is led by founder and CEO Eline Vrijland-van Beest and has recently strengthened its board and management with industry hires.

Participated · Equity · May 2012

Agendia develops and markets genomic diagnostic products for oncology, including the MammaPrint 70-gene risk-of-recurrence test and the BluePrint molecular subtyping test, both on microarray technology, plus a new MammaPrint BluePrint test on NGS. Led by CEO Mark R. Straley and based in Irvine, CA and Amsterdam, the company also has a pipeline of additional genomic products in development. Agendia collaborates with pharmaceutical companies, cancer centers and academic groups to develop companion diagnostics. The company plans to use new financing to accelerate commercial expansion in the U.S. and international markets and to increase adoption of its sequencing-based MammaPrint BluePrint kit. It will invest in Big Data programs, including full-genome profiling trials FLEX (U.S.) and PRECiSE (Netherlands), and establish collaborative research programs with academic institutions to advance its precision oncology pipeline. Agendia develops and markets genomic-based cancer diagnostic products, principally the Symphony™ suite of breast cancer tests including MammaPrint and BluePrint. MammaPrint is FDA‑cleared and is described in the release as the company’s flagship, fastest‑growing, cost‑effective breast cancer recurrence assay; Symphony also includes TargetPrint and TheraPrint for molecular subtyping and therapy selection. The company was formed in 2003 as a spin‑out from the Netherlands Cancer Institute and is privately owned. In March 2014 Norgine Ventures led a €15 million debt financing to help accelerate Agendia’s commercial expansion in the US, Europe and Asia. Agendia operates a direct sales team in the US, the Netherlands, Italy, Germany, Switzerland and Austria, with a distributor network servicing the rest of the world. The company maintains a pipeline of genomic products and collaborates with pharmaceutical companies, leading cancer centres and academic groups on companion diagnostics and trials such as ISPY‑2 and MINDACT. Agendia develops and markets genomic-based diagnostic products to help support physicians with complex treatment decisions. Its breast cancer Symphony suite includes MammaPrint (an FDA-cleared IVDMIA breast cancer recurrence assay), BluePrint, TargetPrint and TheraPrint. The company recently launched the Symphony suite and plans to expand its commercialization. Agendia is also developing a personalized medicine pipeline and is preparing to launch ColoPrint, a recurrence test for stage II colon cancer prognosis and prediction. The company is led by CEO David Macdonald and is based in Boston, MA. It raised $65M in equity financing to support these commercialization and development efforts. Agendia develops molecular diagnostic tests for cancer, including MammaPrint, an in vitro diagnostic multivariate index assay (IVDMIA). The company plans to use the recent proceeds to accelerate commercialization of MammaPrint in the U.S. market. Agendia announced the closing of a $23m Series E financing to support that effort. The round included a lead investment from an undisclosed firm that provided approximately 50% of the funds, two independent entrepreneurs who invested $1m each, and additional capital from the company’s existing investor base. Dr. Bernhard Sixt, President and CEO, commented that the proceeds will be used to accelerate U.S. commercialization. The company is based in Huntington Beach, California, and in Amsterdam, The Netherlands.